Symphogen’s research and development activities in the immuno-oncology area are focused on employing its antibody discovery and screening methodology against a number of targets demonstrated to be involved in cancer development and progression via negative regulation of the immune system, such as immune checkpoints found on immune cells.
PD1, LAG3 and TIM3 are immune checkpoints playing important roles in regulating immune responses, including the body’s immune response to tumor cells.
By June 2018, one Phase 1 trial with Sym022 had been initiated under an agreement with Servier.
Clinical development of Sym022
The primary purpose of this Phase 1 trial is to determine if Sym022 is safe and tolerable for patients with locally advanced/ unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Preclinical data for Sym022 were presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 (Abstract #5626).
Identifying I/O targets
We have generated antibodies against a whole panel of immuno-oncology targets with the aim of identifying novel proprietary mAbs and mAb mixtures. Our goal is to identify and develop drug candidates that can provide therapeutic options for patients whose tumors fail to respond or become resistant to first generation immuno-oncology drugs, such as anti-PD1, anti-PD-L1 and/or anti-CTLA-4 antibodies.